cfDNA or ctDNA Measurement

OTHER2 trials

Conditions

Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial CarcinomaMuscle Invasive Urethral Urothelial CarcinomaResectable Colorectal CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Colorectal Cancer AJCC v8Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

Phase 2

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

RecruitingNCT05987241

National Cancer Institute (NCI)Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma +4

Start: 2024-02-02End: 2030-09-02Target: 992Updated: 2026-09-18

Unknown Phase

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

RecruitingNCT07125729

City of Hope Medical CenterResectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8 +1

Start: 2025-08-29End: 2028-01-09Target: 150Updated: 2026-08-12

cfDNA or ctDNA Measurement

Sponsors

Conditions

Phase 2

Unknown Phase